Page last updated: 2024-10-24

celecoxib and Alveolar Bone Atrophy

celecoxib has been researched along with Alveolar Bone Atrophy in 4 studies

Research Excerpts

ExcerptRelevanceReference
"Alveolar bone loss was evaluated morphometrically under a stereomicroscope."5.35The effects of selective COX-2 inhibitor/celecoxib and omega-3 fatty acid on matrix metalloproteinases, TIMP-1, and laminin-5gamma2-chain immunolocalization in experimental periodontitis. ( Atilla, G; Baylas, H; Buduneli, E; Buduneli, N; Sorsa, T; Turkoglu, O; Vardar-Sengul, S; Wahlgren, J, 2008)
"The aim of this study was to evaluate the effects of selective cyclooxygenase-2 inhibitor, celecoxib, and omega-3 fatty acid on serum levels of interleukin 1-beta (IL-1beta), osteocalcin (OC), and C-reactive protein (CRP) in experimental periodontitis."3.73Effects of selective cyclooxygenase-2 inhibitor and omega-3 fatty acid on serum interleukin-1beta, osteocalcin, and C-reactive protein levels in rats. ( Atilla, G; Baylas, H; Buduneli, E; Buduneli, N; Kinane, DF; Lappin, D; Vardar-Sengül, S, 2006)
"These data provide evidence that systemic therapy with celecoxib can modify the progression of experimentally induced periodontitis in rats."3.71Effect of selective cyclooxygenase-2 inhibition on the development of ligature-induced periodontitis in rats. ( Holzhausen, M; Marcantonio Júnior, E; Nassar, PO; Rossa Júnior, C; Spolidório, DM; Spolidório, LC, 2002)
"Alveolar bone loss was evaluated morphometrically under a stereomicroscope."1.35The effects of selective COX-2 inhibitor/celecoxib and omega-3 fatty acid on matrix metalloproteinases, TIMP-1, and laminin-5gamma2-chain immunolocalization in experimental periodontitis. ( Atilla, G; Baylas, H; Buduneli, E; Buduneli, N; Sorsa, T; Turkoglu, O; Vardar-Sengul, S; Wahlgren, J, 2008)
"Arachidonic acid metabolites have been implicated in development of periodontal disease, especially those derived from the cyclo-oxygenase (COX) pathway."1.35Role of systemic and local administration of selective inhibitors of cyclo-oxygenase 1 and 2 in an experimental model of periodontal disease in rats. ( Caliari, MV; Duarte, ID; Francischi, JN; Maltos, KL; Pacheco, CM; Queiroz-Junior, CM, 2009)

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Vardar-Sengul, S2
Buduneli, E2
Turkoglu, O1
Buduneli, N2
Atilla, G2
Wahlgren, J1
Sorsa, T1
Baylas, H2
Queiroz-Junior, CM1
Pacheco, CM1
Maltos, KL1
Caliari, MV1
Duarte, ID1
Francischi, JN1
Holzhausen, M1
Rossa Júnior, C1
Marcantonio Júnior, E1
Nassar, PO1
Spolidório, DM1
Spolidório, LC1
Lappin, D1
Kinane, DF1

Other Studies

4 other studies available for celecoxib and Alveolar Bone Atrophy

ArticleYear
The effects of selective COX-2 inhibitor/celecoxib and omega-3 fatty acid on matrix metalloproteinases, TIMP-1, and laminin-5gamma2-chain immunolocalization in experimental periodontitis.
    Journal of periodontology, 2008, Volume: 79, Issue:10

    Topics: Alveolar Bone Loss; Animals; Celecoxib; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Drug Co

2008
Role of systemic and local administration of selective inhibitors of cyclo-oxygenase 1 and 2 in an experimental model of periodontal disease in rats.
    Journal of periodontal research, 2009, Volume: 44, Issue:2

    Topics: Alveolar Bone Loss; Animals; Arachidonic Acid; Celecoxib; Cyclooxygenase Inhibitors; Disease Models,

2009
Effect of selective cyclooxygenase-2 inhibition on the development of ligature-induced periodontitis in rats.
    Journal of periodontology, 2002, Volume: 73, Issue:9

    Topics: Alveolar Bone Loss; Analysis of Variance; Animals; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inh

2002
Effects of selective cyclooxygenase-2 inhibitor and omega-3 fatty acid on serum interleukin-1beta, osteocalcin, and C-reactive protein levels in rats.
    Journal of periodontology, 2006, Volume: 77, Issue:4

    Topics: Alveolar Bone Loss; Animals; C-Reactive Protein; Celecoxib; Cyclooxygenase 2 Inhibitors; Endotoxins;

2006